Innovative Dual Vector Gene Therapy Shows Promise for Treating Tay-Sachs and Sandhoff Diseases

Researchers at UMass Chan Medical School have conducted a promising Phase I/II clinical trial exploring a novel dual vector gene therapy targeting GM2 gangliosidosis, including the devastating diseases Tay-Sachs and Sandhoff. The study involved nine participants who received injections of two harmless viral vectors into the thalamus and spinal cord. These vectors deliver genetic instructions enabling brain cells to produce the missing enzyme, beta-hexosaminidase A (HexA), crucial for breaking down GM2 gangliosides that accumulate and damage nerve cells in these conditions.

The trial results, published in Nature Medicine, demonstrated biochemical correction, with increased enzyme activity surpassing twice the lower limit of normal. Participants also experienced improved clinical outcomes, such as prolonged ability to feed orally and fewer, less severe seizures. Importantly, the treatment was well tolerated, with minimal adverse effects.

According to study lead Heather Gray-Edwards, DVM, Ph.D., the injections proved safe and effective in stimulating enzyme production, marking a significant advancement. The research team plans to enhance the therapy further by developing a single-vector approach to increase the therapeutic DNA delivered without elevating the vector volume, which could facilitate early intervention and potentially improve long-term outcomes.

GM2 gangliosidosis is a genetic disorder caused by mutations in the HEXA or GM2A gene, leading to deficient HexA enzyme. Without this enzyme, GM2 gangliosides accumulate in nerve cells, causing progressive neurodegeneration. The condition usually manifests in infancy with symptoms such as developmental regression, seizures, and loss of motor skills, often resulting in death within a few years. Currently, there are no effective treatments for this fatal disease.

This breakthrough reflects the dedicated efforts of scientists like Dr. Gray-Edwards and Dr. Sena-Esteves, whose work in gene therapy is paving the way for future cures. The dual vector therapy aims to deliver long-term enzyme production, preventing neuronal death and improving quality of life. The upcoming focus is on refining the delivery method to optimize safety and efficacy, with hopes of offering early treatment options for affected children.

For more information, see the original study: Florian Eichler et al., 'Dual-vector rAAVrh8 gene therapy for GM2 gangliosidosis: a phase 1/2 trial,' Nature Medicine (2025).